Attorney General Ellison secures $720 million from eight opioid drug makers

Minnesota could receive over $9 million from the settlement, bringing state’s total from opioid settlements up to $633 million

July 10, 2025 (SAINT PAUL) — Attorney General Ellison today announced approximately $720 million nationwide in settlements with eight drug makers that manufactured opioid pills and worsened the nationwide opioid crisis. Minnesota could receive up to $9,370,000 million from the settlements, which would bring the total Minnesota will receive from settlements with opioid companies to $633 million. 

“No amount of money can undo the tremendous harm that opioid manufacturers and peddlers have inflicted on families across Minnesota,” said Attorney General Keith Ellison. “However, it is still important that we hold wrongdoers accountable for their actions and help those who are suffering, which these settlements do. I will continue to aggressively pursue accountability from these companies and ensure the money they made by pushing opioids is brought back to Minnesota and used on treatment, recovery, and prevention.”

According to the terms of an agreement the Attorney General’s Office reached with Minnesota cities and counties in December 2021, 75% of opioid settlement funds Minnesota receives are allocated to city and county governments and 25% of funds are allocated to the State. The agreement also details how the funds can be used to combat the opioid crisis, including detailed programs and strategies focused on treatment, prevention, and harm reduction. 

With these settlements, Attorney General Ellison’s Office has obtained roughly $633 million for Minnesota local governments and the State of Minnesota from companies that helped fuel the opioid epidemic.

The eight defendants and the total amount they will pay in funds to address the opioid crisis as part of the deal are:  

• Mylan (now part of Viatris): $284,447,916 paid over nine years 
• Hikma: $95,818,293 paid over one to four years 
• Amneal: $71,751,010 paid over 10 years 
• Apotex: $63,682,369 paid in a single year 
• Indivior: $38,022,450 paid over four years 
• Sun: $30,992,087 paid over one to four years 
• Alvogen: $18,680,162 paid in a single year 
• Zydus: $14,859,220 paid in a single year 

Additionally, seven of the companies (not including Indivior) are prohibited from promoting or marketing opioids and opioid products, making or selling any product that contains more than 40 mg of oxycodone per pill, and are required to put in place a monitoring and reporting system for suspicious orders. Indivior has agreed to not manufacture or sell opioid products for the next 10 years, but it will be able to continue marketing and selling medications to treat opioid use disorder.

The settlements were negotiated by North Carolina, California, Colorado, Illinois, New York, Oregon, Tennessee, Utah, and Virginia.